The large institutional money is starting to place bets on life sciences on both sides of the Atlantic

"At this point in the US, life sciences is an asset class that you can't ignore anymore," says Nicole Riley, a counsel in Goodwin's Business Law Department and a member of its Real Estate Industry group. "We have folks who are asking us how to look at this asset class from an underwriting perspective."

Given the current economic conditions, Riley is even more surprised by the inflow of capital into the sector. In October, 29 life science funds had closed almost $16 billion, according to Riley. 

Want to continue reading?
Become a Free ALM Digital Reader.

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Leslie Shaver

Les Shaver has been covering commercial and residential real estate for almost 20 years. His work has appeared in Multifamily Executive, Builder, units, Arlington Magazine in addition to GlobeSt.com and Real Estate Forum.